Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial nephrectomy, though anatomical details would still require conventional imaging.
Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need for systemic therapy rather than surgery alone.
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.
N6-methyladenosine (m6A) has been established as a critical regulator in various human cancers. However, the role of m6A modification in renal cell carcinoma (RCC) and its interaction with long non-coding RNA LHX1-DT (LHX1-DT) remains unclear. Differentially expressed lncRNAs and m6A levels ...
Panelists discuss how new molecular imaging technology offers potential to better risk stratify patients eligible for adjuvant pembrolizumab after surgery, potentially identifying those who have undetected metastatic disease requiring more aggressive treatment.
Panelists discuss how the ZIRCON trial results showed impressive test characteristics with 95% positive predictive value for clear cell renal cell carcinoma, meaning a positive test strongly indicates cancer requiring treatment.
The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.